Characteristics and Outcomes of BI-RADS 3 Lesions on Breast MRI

Babita Panigrahi, Susan Harvey, Lisa Mullen, Eniola Falomo, Philip Di Carlo, Bonmyong Lee, Kelly Myers

Research output: Contribution to journalArticle

Abstract

Background: There are few data regarding the use and outcomes of Breast Imaging Reporting and Data System (BI-RADS) 3 assessment on breast magnetic resonance imaging (MRI). The aim of this study was to describe the imaging findings prompting a BI-RADS 3 assessment and to report their outcomes, including the timing of follow-up examinations. Patients and Methods: We performed a retrospective study evaluating 199 breast lesions in 186 patients who were assigned a BI-RADS 3 assessment on breast MRI over a 5-year period. Clinical and imaging features were recorded. For outcomes analysis, lesions were considered benign if they showed 2 years of MRI stability, if they were declared benign during follow-up, or if the patient underwent biopsy with benign pathology results. Clinical and imaging features of BI-RADS 3 lesions associated with malignancy were assessed by the Fisher exact test, with P < .05 considered significant. Results: Of the 199 breast MRI lesions assigned a BI-RADS 3 assessment, 80 (40%) of 199 were non–mass enhancement, 61 (31%) were a single focus, and 58 (29%) were masses. A total of 131 lesions (66%) were eligible for outcome analysis after excluding those lost to follow-up; 4 (3%) were diagnosed as malignant within the 2-year follow-up. Masses assigned a BI-RADS 3 assessment were more likely to be malignant during follow-up than non–mass enhancement or single focus (P < .05). Conclusion: Despite limited data on the use of BI-RADS 3 at breast MRI, there is a low malignancy rate of 3% at our institution. Additional studies are needed to further define the appropriate use of BI-RADS 3 on breast MRI. In a study of the imaging findings prompting a Breast Imaging Reporting and Data System (BI-RADS) 3 assessment and reports of their outcomes, we assessed 199 breast MRI lesions assigned a BI-RADS 3 assessment. Of these, 80 (40%) of 199 were non–mass enhancement, 61 (31%) of 199 were a single focus and 58 (29%) of 199 were masses; of the 131 lesions with appropriate follow-up, 4 (3%) were diagnosed as malignant within a 2-year follow-up period. Despite limited data on the use of BI-RADS 3 at breast MRI, there is a low malignancy rate of 3%.

Original languageEnglish (US)
JournalClinical Breast Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Information Systems
Breast
Magnetic Resonance Imaging
Neoplasms
Lost to Follow-Up

Keywords

  • Magnetic resonance imaging
  • Malignancy rate
  • Short term follow-up

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Characteristics and Outcomes of BI-RADS 3 Lesions on Breast MRI. / Panigrahi, Babita; Harvey, Susan; Mullen, Lisa; Falomo, Eniola; Di Carlo, Philip; Lee, Bonmyong; Myers, Kelly.

In: Clinical Breast Cancer, 01.01.2018.

Research output: Contribution to journalArticle

@article{9ccb947545724959bc32d9e2f7902ed9,
title = "Characteristics and Outcomes of BI-RADS 3 Lesions on Breast MRI",
abstract = "Background: There are few data regarding the use and outcomes of Breast Imaging Reporting and Data System (BI-RADS) 3 assessment on breast magnetic resonance imaging (MRI). The aim of this study was to describe the imaging findings prompting a BI-RADS 3 assessment and to report their outcomes, including the timing of follow-up examinations. Patients and Methods: We performed a retrospective study evaluating 199 breast lesions in 186 patients who were assigned a BI-RADS 3 assessment on breast MRI over a 5-year period. Clinical and imaging features were recorded. For outcomes analysis, lesions were considered benign if they showed 2 years of MRI stability, if they were declared benign during follow-up, or if the patient underwent biopsy with benign pathology results. Clinical and imaging features of BI-RADS 3 lesions associated with malignancy were assessed by the Fisher exact test, with P < .05 considered significant. Results: Of the 199 breast MRI lesions assigned a BI-RADS 3 assessment, 80 (40{\%}) of 199 were non–mass enhancement, 61 (31{\%}) were a single focus, and 58 (29{\%}) were masses. A total of 131 lesions (66{\%}) were eligible for outcome analysis after excluding those lost to follow-up; 4 (3{\%}) were diagnosed as malignant within the 2-year follow-up. Masses assigned a BI-RADS 3 assessment were more likely to be malignant during follow-up than non–mass enhancement or single focus (P < .05). Conclusion: Despite limited data on the use of BI-RADS 3 at breast MRI, there is a low malignancy rate of 3{\%} at our institution. Additional studies are needed to further define the appropriate use of BI-RADS 3 on breast MRI. In a study of the imaging findings prompting a Breast Imaging Reporting and Data System (BI-RADS) 3 assessment and reports of their outcomes, we assessed 199 breast MRI lesions assigned a BI-RADS 3 assessment. Of these, 80 (40{\%}) of 199 were non–mass enhancement, 61 (31{\%}) of 199 were a single focus and 58 (29{\%}) of 199 were masses; of the 131 lesions with appropriate follow-up, 4 (3{\%}) were diagnosed as malignant within a 2-year follow-up period. Despite limited data on the use of BI-RADS 3 at breast MRI, there is a low malignancy rate of 3{\%}.",
keywords = "Magnetic resonance imaging, Malignancy rate, Short term follow-up",
author = "Babita Panigrahi and Susan Harvey and Lisa Mullen and Eniola Falomo and {Di Carlo}, Philip and Bonmyong Lee and Kelly Myers",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2018.08.011",
language = "English (US)",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - Characteristics and Outcomes of BI-RADS 3 Lesions on Breast MRI

AU - Panigrahi, Babita

AU - Harvey, Susan

AU - Mullen, Lisa

AU - Falomo, Eniola

AU - Di Carlo, Philip

AU - Lee, Bonmyong

AU - Myers, Kelly

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: There are few data regarding the use and outcomes of Breast Imaging Reporting and Data System (BI-RADS) 3 assessment on breast magnetic resonance imaging (MRI). The aim of this study was to describe the imaging findings prompting a BI-RADS 3 assessment and to report their outcomes, including the timing of follow-up examinations. Patients and Methods: We performed a retrospective study evaluating 199 breast lesions in 186 patients who were assigned a BI-RADS 3 assessment on breast MRI over a 5-year period. Clinical and imaging features were recorded. For outcomes analysis, lesions were considered benign if they showed 2 years of MRI stability, if they were declared benign during follow-up, or if the patient underwent biopsy with benign pathology results. Clinical and imaging features of BI-RADS 3 lesions associated with malignancy were assessed by the Fisher exact test, with P < .05 considered significant. Results: Of the 199 breast MRI lesions assigned a BI-RADS 3 assessment, 80 (40%) of 199 were non–mass enhancement, 61 (31%) were a single focus, and 58 (29%) were masses. A total of 131 lesions (66%) were eligible for outcome analysis after excluding those lost to follow-up; 4 (3%) were diagnosed as malignant within the 2-year follow-up. Masses assigned a BI-RADS 3 assessment were more likely to be malignant during follow-up than non–mass enhancement or single focus (P < .05). Conclusion: Despite limited data on the use of BI-RADS 3 at breast MRI, there is a low malignancy rate of 3% at our institution. Additional studies are needed to further define the appropriate use of BI-RADS 3 on breast MRI. In a study of the imaging findings prompting a Breast Imaging Reporting and Data System (BI-RADS) 3 assessment and reports of their outcomes, we assessed 199 breast MRI lesions assigned a BI-RADS 3 assessment. Of these, 80 (40%) of 199 were non–mass enhancement, 61 (31%) of 199 were a single focus and 58 (29%) of 199 were masses; of the 131 lesions with appropriate follow-up, 4 (3%) were diagnosed as malignant within a 2-year follow-up period. Despite limited data on the use of BI-RADS 3 at breast MRI, there is a low malignancy rate of 3%.

AB - Background: There are few data regarding the use and outcomes of Breast Imaging Reporting and Data System (BI-RADS) 3 assessment on breast magnetic resonance imaging (MRI). The aim of this study was to describe the imaging findings prompting a BI-RADS 3 assessment and to report their outcomes, including the timing of follow-up examinations. Patients and Methods: We performed a retrospective study evaluating 199 breast lesions in 186 patients who were assigned a BI-RADS 3 assessment on breast MRI over a 5-year period. Clinical and imaging features were recorded. For outcomes analysis, lesions were considered benign if they showed 2 years of MRI stability, if they were declared benign during follow-up, or if the patient underwent biopsy with benign pathology results. Clinical and imaging features of BI-RADS 3 lesions associated with malignancy were assessed by the Fisher exact test, with P < .05 considered significant. Results: Of the 199 breast MRI lesions assigned a BI-RADS 3 assessment, 80 (40%) of 199 were non–mass enhancement, 61 (31%) were a single focus, and 58 (29%) were masses. A total of 131 lesions (66%) were eligible for outcome analysis after excluding those lost to follow-up; 4 (3%) were diagnosed as malignant within the 2-year follow-up. Masses assigned a BI-RADS 3 assessment were more likely to be malignant during follow-up than non–mass enhancement or single focus (P < .05). Conclusion: Despite limited data on the use of BI-RADS 3 at breast MRI, there is a low malignancy rate of 3% at our institution. Additional studies are needed to further define the appropriate use of BI-RADS 3 on breast MRI. In a study of the imaging findings prompting a Breast Imaging Reporting and Data System (BI-RADS) 3 assessment and reports of their outcomes, we assessed 199 breast MRI lesions assigned a BI-RADS 3 assessment. Of these, 80 (40%) of 199 were non–mass enhancement, 61 (31%) of 199 were a single focus and 58 (29%) of 199 were masses; of the 131 lesions with appropriate follow-up, 4 (3%) were diagnosed as malignant within a 2-year follow-up period. Despite limited data on the use of BI-RADS 3 at breast MRI, there is a low malignancy rate of 3%.

KW - Magnetic resonance imaging

KW - Malignancy rate

KW - Short term follow-up

UR - http://www.scopus.com/inward/record.url?scp=85053879308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053879308&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2018.08.011

DO - 10.1016/j.clbc.2018.08.011

M3 - Article

C2 - 30268764

AN - SCOPUS:85053879308

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -